(3R,5S)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,5S)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₁H₂₅ClO₆
• 分子量: 408.9
• InChiKey: JVHXJTBJCFBINQ-KWJZQVHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
  申请人：AstraZeneca AB

  公开号：US20140243262A1

  公开（公告）日：2014-08-28

  Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.

  提供药物制剂，为口服胶囊或片剂形式，包括一种药物达格列净或其丙二醇水合物，以及一种药用可接受的载体，该制剂旨在立即释放。
• CRYSTALLINE FORMS AND METHODS FOR PREPARING SGLT2 INHIBITORS
  申请人：MSD International GmbH

  公开号：EP3466431A1

  公开（公告）日：2019-04-10

  This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.

  本发明涉及钠-葡萄糖转运体 2（SGLT2）抑制剂、共晶 SGLT2 和（S）-5-氧代吡咯烷-2-羧酸（L-PGA）复合物以及用于制备上述 SGLT2 抑制剂的中间体的制备方法。
• Bilayer Tablet Formulations
  申请人：AstraZeneca AB

  公开号：US20150238421A1

  公开（公告）日：2015-08-27

  The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
• Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
  申请人：AstraZeneca AB

  公开号：US20170135981A1

  公开（公告）日：2017-05-18

  Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. The present invention also relates to methods for treating diabetes, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis and related diseases, comprising administering an SGLT2 inhibitor and a dipeptidyl peptidase IV (DPP IV) inhibitor.
• US9198925B2
  申请人：——

  公开号：US9198925B2

  公开（公告）日：2015-12-01